Skip to main content
. 2022 Jan 10;13:182. doi: 10.1038/s41467-021-27833-0

Fig. 4. Intermittent BAY1082439 treatment induces tumor-associated CD8+ T cell clonal expansion and activation of the IL-2 and TCR signing pathways.

Fig. 4

AC. A schematic illustration of treatment procedures and the percentages of CD8+ in CD45+ in peripheral blood and the prostates. Pten-null mice were treated with vehicle (n = 6), S1PR modulator Fingolimod alone (n = 5) or in combination with BAY-I (n = 6) for 4 weeks. CD45+ and CD8+ T cells from peripheral blood or the prostates were sorted and presented as the percentage of CD8+ in CD45+ cells. D BAY-I treatment induced CD8+ T cell proliferation. Pten-null mice was treated with vehicle (n = 7) or BAY-I (n = 7) for 2 weeks, then BrdU labeled (10 mg single dose) for 24 h before analyzing the percentages of BrdU+ cells in CD8+ T cell by FACS analysis. E BAY-I treatment induced CD8+ T cell activation. Castrated Pten-null mice were treated with vehicle (n = 6), BAY-D (n = 7) or BAY-I (n = 9) for 4 weeks, and tumor-associated CD8+ T cells were sorted then analyzed by RNA-seq. The relative expression levels of Il2, Cd25 and Cd40l were presented. F GSEA analysis of IL2 and TCR single pathway between Vehicle and BAY-I/BAY-D group. Statistical test was performed by GSEA. Data were presented as dot plots with mean as the central lines (for A, B, C and D) or as mean ± SEM (for E); *p < 0.05, **p < 0.01, ***p < 0.001 by two-sided T-test. Source data and exact p values are provided in the Source Data file.

HHS Vulnerability Disclosure